(Q38059436)

English

New treatments for IBS.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

New treatments for IBS. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Nicholas Talley

2

object named as

Nicholas J Talley

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Magnus Halland

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

13 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Nature Reviews Gastroenterology & Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

13-23

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

https://scigraph.springernature.com/pub.10.1038/nrgastro.2012.207

0 references

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The impact of functional gastrointestinal disorders on quality of life.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Suicidal ideation in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The economic consequences of irritable bowel syndrome: a US employer perspective

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Postinfectious irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Psychosocial factors at work and in every day life are associated with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Placebos without deception: a randomized controlled trial in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Investigating placebo effects in irritable bowel syndrome: a novel research design.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Self-management for women with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The treatment of irritable bowel syndrome with hypnotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Mood color choice helps to predict response to hypnotherapy in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Acupuncture for irritable bowel syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Food-related gastrointestinal symptoms in the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Exercise in fibromyalgia

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A placebo-controlled trial of prucalopride for severe chronic constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of linaclotide for patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Rifaximin therapy for patients with irritable bowel syndrome without constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Involvement of kappa-opioid receptors in visceral nociception in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Bile acids and colonic motility in the rabbit and the human

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Treatment of irritable bowel syndrome-diarrhea with pancrealipase or colesevelam and association with steatorrhea.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Review article: new receptor targets for medical therapy in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Fecal microbiota transplantation and emerging applications

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Hypnotherapy for functional gastrointestinal disorders: a review

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

IBS: Hypnotherapy--a wasted resource?

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Lubiprostone: trials and tribulations.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Organic and functional disorders in 2000 gastroenterology outpatients

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Presidential address: Gastrointestinal illness and the biopsychosocial model

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Herbal medicines for treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

The functional gastrointestinal disorders and the Rome III process

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Novartis suspends tegaserod sales at FDA's request

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Effects of β-(1,3-1,6)-D-glucan on irritable bowel syndrome-related colonic hypersensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

31 March 2020

Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidemiology of irritable bowel syndrome in North America: a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptomatology, quality of life and economic features of irritable bowel syndrome--the effect of hypnotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impairment in work productivity and health-related quality of life in patients with IBS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irritable bowel syndrome: toward a cost-effective management approach.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in managed care patients with irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRGASTRO.2012.207

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38059436&oldid=1575667995"